Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
| LYFAX Fund | USD 13.70 0.04 0.29% |
Slightly above 54% of Alphacentric Lifesci's investor base is interested to short. The analysis of overall sentiment of trading Alphacentric Lifesci Healthcare mutual fund suggests that many investors are impartial at this time. Alphacentric Lifesci's investing sentiment can be driven by a variety of factors including economic data, Alphacentric Lifesci's earnings reports, geopolitical events, and overall market trends.
Alphacentric |
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-vals substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical b
Read at finance.yahoo.com
 |
Alphacentric Lifesci Fundamental Analysis
We analyze Alphacentric Lifesci's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alphacentric Lifesci using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alphacentric Lifesci based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Year To Date Return
Year To Date Return Comparative Analysis
Alphacentric Lifesci is currently under evaluation in year to date return among similar funds. Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
Alphacentric Lifesci Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alphacentric Lifesci mutual fund to make a market-neutral strategy. Peer analysis of Alphacentric Lifesci could also be used in its relative valuation, which is a method of valuing Alphacentric Lifesci by comparing valuation metrics with similar companies.
Peers
Alphacentric Lifesci Related Equities
| SHSKX | Blackrock Health | 0.49 | ||||
| SHISX | Blackrock Health | 0.27 | ||||
| ITRAX | Vy(r) T | 0.04 | ||||
| ERSMX | Eaton Vance | 0.33 |
Other Information on Investing in Alphacentric Mutual Fund
Alphacentric Lifesci financial ratios help investors to determine whether Alphacentric Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alphacentric with respect to the benefits of owning Alphacentric Lifesci security.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |